Trianni, Inc. (“TRIANNI”) and Mablytics, Inc. (“MABLYTICS”) jointly announced today that they have entered into a license agreement for the use of the Trianni Mouse®, a transgenic mouse R&D platform for the discovery of fully-human monoclonal antibodies, to support MABLYTICS’ antibody-based therapeutic discovery programs.
| SAN FRANCISCO and BOSTON, Feb. 4, 2020 /PRNewswire/ -- TRIANNI, Inc. (“TRIANNI”) and Mablytics, Inc. (“MABLYTICS”) jointly announced today that they have entered into a license agreement for the use of the Trianni Mouse®, a transgenic mouse R&D platform for the discovery of fully-human monoclonal antibodies, to support MABLYTICS’ antibody-based therapeutic discovery programs.
“TRIANNI is pleased that Mablytics has chosen the Trianni Mouse for the development of novel, fully human, antibody-based therapeutics,” said Matthias Wabl, PhD, Chairman, President and CEO of TRIANNI. “We are confident that the TRIANNI discovery platform, which combines the complete human antibody repertoire with wild-type mouse immune responses to any target antigen, will be a great asset for Mablytics’ drug discovery programs.” “We look forward to utilizing TRIANNI’s technology to progress our drug development efforts targeting a novel oncology target,” stated Sundar Subramaniam, CEO of MABLYTICS. No financial details were disclosed. About Trianni, Inc. About MABLYTICS Contacts: Trianni, Inc. Contacts: MABLYTICS, Inc.
SOURCE Trianni, Inc. |
View original content to download multimedia:
